TR199902449T2 - Farmakolojik etkin maddeler. - Google Patents

Farmakolojik etkin maddeler.

Info

Publication number
TR199902449T2
TR199902449T2 TR1999/02449T TR9902449T TR199902449T2 TR 199902449 T2 TR199902449 T2 TR 199902449T2 TR 1999/02449 T TR1999/02449 T TR 1999/02449T TR 9902449 T TR9902449 T TR 9902449T TR 199902449 T2 TR199902449 T2 TR 199902449T2
Authority
TR
Turkey
Prior art keywords
active substances
pharmacologically active
selective
antagonists
glur5 receptor
Prior art date
Application number
TR1999/02449T
Other languages
English (en)
Inventor
Bleakman David
R. Helton David
Iyengar Smriti
Lodge David
Leslie Ornstein Paul
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199902449T2 publication Critical patent/TR199902449T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

GluR5 reseptörü için seçici antagonistler olup, agri tedavisinde kullanilmaktadir. Yeni dekahidroizokuinolin türevleri de tarif edilmekte olup, seçici GluR5 reseptörü antagonistleridirler.
TR1999/02449T 1997-04-07 1998-04-06 Farmakolojik etkin maddeler. TR199902449T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4279597P 1997-04-07 1997-04-07

Publications (1)

Publication Number Publication Date
TR199902449T2 true TR199902449T2 (tr) 2000-07-21

Family

ID=21923795

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02449T TR199902449T2 (tr) 1997-04-07 1998-04-06 Farmakolojik etkin maddeler.

Country Status (17)

Country Link
US (1) US6242462B1 (tr)
EP (1) EP0980358A4 (tr)
JP (1) JP2001521505A (tr)
KR (1) KR20010006075A (tr)
CN (1) CN1259126A (tr)
AU (1) AU734657B2 (tr)
BR (1) BR9809071A (tr)
CA (1) CA2285192A1 (tr)
EA (1) EA199900912A1 (tr)
HU (1) HUP0002030A3 (tr)
ID (1) ID23013A (tr)
IL (1) IL132086A0 (tr)
NO (1) NO994850L (tr)
NZ (1) NZ337827A (tr)
PL (1) PL336068A1 (tr)
TR (1) TR199902449T2 (tr)
WO (1) WO1998045270A1 (tr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230174C (zh) 1999-07-06 2005-12-07 伊莱利利公司 治疗偏头痛的选择性iGluR5受体拮抗剂
ATE240299T1 (de) 1999-07-06 2003-05-15 Lilly Co Eli Diester prodrugs von decahydroischinoline-3- carbonsäure
EP1257545A1 (en) 1999-12-22 2002-11-20 Eli Lilly And Company SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS
US6855725B2 (en) 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
MXPA03005982A (es) * 2001-01-05 2003-09-10 Lilly Co Eli Antagonistas de receptores de aminoacidos excitadores.
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6953805B2 (en) 2001-01-05 2005-10-11 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002058691A1 (en) * 2001-01-23 2002-08-01 Neurosearch A/S Use of non-competitive and selective glur5 antagonists as glutamate receptor modulating compounds
DK1511741T3 (da) 2002-04-26 2013-01-21 Lilly Co Eli Esterderivater af en decahydroisoquinolin-3-carboxylsyre som analgetika
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
CA2580730C (en) * 2003-09-25 2015-01-13 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
CA2686816A1 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR101746944B1 (ko) * 2015-09-23 2017-06-14 주식회사 포스코 도장 선영성이 우수한 도금강판의 제조방법 및 이에 의해 제조된 도금강판

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5731348A (en) * 1995-02-15 1998-03-24 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor

Also Published As

Publication number Publication date
EA199900912A1 (ru) 2000-04-24
HUP0002030A2 (hu) 2001-04-28
PL336068A1 (en) 2000-06-05
EP0980358A4 (en) 2001-02-07
AU6955598A (en) 1998-10-30
US6242462B1 (en) 2001-06-05
CA2285192A1 (en) 1998-10-15
HUP0002030A3 (en) 2002-01-28
ID23013A (id) 1999-12-30
AU734657B2 (en) 2001-06-21
BR9809071A (pt) 2000-08-01
IL132086A0 (en) 2001-03-19
CN1259126A (zh) 2000-07-05
KR20010006075A (ko) 2001-01-15
JP2001521505A (ja) 2001-11-06
NZ337827A (en) 2000-12-22
WO1998045270A1 (en) 1998-10-15
NO994850D0 (no) 1999-10-05
EP0980358A1 (en) 2000-02-23
NO994850L (no) 1999-10-05

Similar Documents

Publication Publication Date Title
EA199900912A1 (ru) Фармацевтические средства
PT911340E (pt) Isoquinolinas-3-carboxamidas substituidas, sua preparacao e utilizacao como farmacos
EP1178786A4 (en) PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
DE60031248D1 (de) Elektroaktive pore
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
NO995135L (no) Fremstilling av höyaktive katalysatorer, katalysatorene og deres anvendelse
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
FR2791678B1 (fr) Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
BR9909486A (pt) Compostos calcilìticos
TR199701645A3 (tr) Vitronektin reseptör antagonistleri,bunlarin imalati ve kullanimi
IT1287174B1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
FR2788518B1 (fr) Nouveaux carbamates actives stables, leur procede de preparation et leur utilisation pour la preparation d'urees
DE69941825D1 (de) Arzneistoffhaltiger kaugummi, dessen herstellungsverfahren und so erhaltene tablette
ATE286883T1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
FR2735475B1 (fr) Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
FR2771093B1 (fr) Derives d'imidazole, leur preparation et leur application en therapeutique
ATE271032T1 (de) Amphiphile polyamin verbindungen
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
FI971528L (fi) Pyrrolyylitetrahydrobentsokinoksaliinidionit, niiden valmistus ja käyttö glutamaattireseptoriantagonisteina